单位(元)招商国证生物医药指数A(161726)利润表 |
报告期 |
2023/12/31 |
2023/6/30 |
2022/12/31 |
2022/6/30 |
收入 |
-2,768,919,027 |
-3,023,348,761 |
-4,587,721,673 |
-2,094,337,520 |
利息收入 |
6,471,968 |
3,227,508 |
10,212,895 |
5,140,757 |
其中:存款利息收入 |
2,441,527 |
1,392,240 |
3,098,039 |
1,584,288 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益 |
-1,067,310,849 |
-361,788,843 |
-1,826,653,675 |
-1,000,301,450 |
其中:股票投资收益 |
-1,183,064,056 |
-447,454,890 |
-1,940,001,951 |
-1,094,143,764 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
1,362,303 |
26,047 |
544,424 |
465,322 |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
114,390,904 |
85,640,000 |
112,803,853 |
93,376,992 |
公允价值变动收益 |
-1,713,720,436 |
-2,668,099,520 |
-2,786,191,696 |
-1,108,492,668 |
汇兑收益 |
- |
- |
- |
- |
其他收入 |
5,640,290 |
3,312,095 |
14,910,802 |
9,315,841 |
费用 |
167,111,326 |
85,698,519 |
181,915,068 |
91,379,669 |
管理人报酬 |
133,943,706 |
68,274,176 |
145,224,351 |
73,003,918 |
托管费 |
28,217,959 |
15,020,319 |
31,949,357 |
16,060,862 |
销售服务费 |
1,981,660 |
894,294 |
1,536,478 |
705,783 |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
2,953,189 |
1,503,019 |
3,179,105 |
1,596,240 |
利润总额 |
-2,936,030,353 |
-3,109,047,280 |
-4,769,636,742 |
-2,185,717,189 |
减:所得税费用 |
- |
- |
- |
- |
净利润 |
-2,936,030,353 |
-3,109,047,280 |
-4,769,636,742 |
-2,185,717,189 |
*注:新浪财经提醒:以上数据由合作伙伴提供,仅供参考,交易请以正式公告数据为准。